<DOC>
	<DOCNO>NCT01103791</DOCNO>
	<brief_summary>This phase I trial determine maximum tolerate dose recommended phase II dose docetaxel-PNP ( polymeric nanoparticle formulation docetaxel ) evaluate safety pharmacokinetics docetaxel-PNP subject advance solid malignancy .</brief_summary>
	<brief_title>A Trial Determine Maximum Tolerated Dose Evaluate Safety Pharmacokinetics Docetaxel-PNP , Polymeric Nanoparticle Formulation Docetaxel , Subjects With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patient age 18 year old Patient voluntarily sign write informed consent study entry Patient historically cytologically confirm diagnosis advance solid tumor patient measurable disease evaluable disease RECIST criterion Progressive disease development new lesion increase preexist lesion standard therapy order provide clinical benefit exist longer effective Previous anticancer therapy must complete 21days first study dose Patient must recover previous therapy Patient Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Patient life expectancy least 3 month Baseline study determine eligibility must complete within 14 day first study dose patient adequate organ function include follow : Hb ≥ 10g/dl ANC ≥ 1.5 X 109/L Platelet count ≥ 100 X 109/L Serum total bilirubin ≤ 1.5 mg/dL Serum AST ALT ≤ 2.5 X UNL Serum ALP ≤ 2.5ⅹUNL Serum creatinine ≤ 1.5 X UNL Patient major surgery except tumor ablation within 2 week screen visit Patient brain metastasis neurologic symptom Patient sensory neuropathy motor neuropathy ≥ grade 2 NCICTCAE Patient serious concurrent disease : Any medical psychiatric condition , opinion investigator , would prohibit understanding give informed consent Severe cardiovascular disease ( e.g . ischemic heart disease require medication myocardial infraction within past six month , grade 34 congestive heart failure define New York Heart Association criterion ) Active un control infection . Patient hypersensitivity Investigational product excipients Patient participate clinical trial within 4 week screen visit Woman pregnant breast feeding Subjects childbearing potential use medically acceptable method birth control agree continue use method throughout trial ( screen , treatment period , 3 week last do ) . A negative pregnancy test ( urine serum ) document within 14 day prior initiation trial medication woman childbearing potential amenorrheic least 12 month prior registration trial surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) . Medically acceptable method include : Barrier method spermicide Intrauterine device Complete abstinence , etc . Patient history resistance , intolerance , response Docetaxel therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>